---
layout: post
title: New Drug Approvals 2012 - Pt. X - Avanafil (StendraTM)
date: '2012-05-01T22:15:00.000+01:00'
author: Patricia
tags:
- Small Molecule Drugs
- 2012 New Drugs
modified_time: '2013-01-02T09:36:21.077Z'
thumbnail: http://4.bp.blogspot.com/-NzZ0vj2DHrs/T569G8kuWYI/AAAAAAAAAp8/DMFKP8WSZl4/s72-c/PDBe_PDE5_sildenafil.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-8587208549798782641
blogger_orig_url: http://chembl.blogspot.com/2012/05/new-drug-approvals-2012-pt-x-avanafil.html
---

<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<br />
<center face="arial">
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,5,0,1,0,0,1,0,0" width="400" /></center>
<center face="arial">
<br />
</center>
<center face="arial">
<b>ATC code</b>:<span class="Apple-style-span" style="font-family: inherit;">&nbsp;<span class="Apple-style-span" style="-webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px; line-height: 18px;">G04BE (partial)</span></span></center>
<center face="arial">
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="-webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px; line-height: 18px;"><b>Wikipedia</b>: <a href="http://en.wikipedia.org/wiki/Avanafil">Avanafil</a></span></span></center>
<br />
<br />
On April 27th, the FDA approved Avanafil (tradename: <a href="http://www.trademarkia.com/trademarks-search.aspx?tn=Stendra">Stendra</a>; Research Code: TA-1790), a <a href="http://en.wikipedia.org/wiki/PDE5_inhibitor">phosphodiesterase 5 (PDE5) inhibitor</a> for the treatment of <a href="http://en.wikipedia.org/wiki/Erectile_dysfunction">erectile dysfunction (ED)</a>.&nbsp;ED is a sexual dysfunction&nbsp;characterized&nbsp;by the inability to produce an erection of the penis. The physiologic mechanism of penile erection involves the release of nitric oxide in the corpus cavernosum during sexual stimulation, which in turn activates the enzyme <a href="http://en.wikipedia.org/wiki/Guanylate_cyclase">guanylate cyclase</a>, resulting in increased levels of <a href="http://en.wikipedia.org/wiki/Cyclic_guanosine_monophosphate">cyclic guanosine monophosphate (cGMP)</a>. cGMP produces relaxation of smooth muscle tissues, which in the corpus cavernosum results in vasodilation and increased blood flow. Avanafil (PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=17397370&amp;viewopt=PubChem">CID9869929</a>, ChemSpider: <a href="http://www.chemspider.com/Chemical-Structure.8045620.html?rid=00c98f74-53ac-47fe-b4b1-fb754b5de64e">8045620</a>) enhances the relaxant effects of cGMP by selectively inhibiting PDE5 (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1827">CHEMBL1827</a>; Uniprot: <a href="http://www.uniprot.org/uniprot/O76074">O76074</a>), an enzyme responsible for the degradation of cGMP.<br />
<div class="p1">
<span class="s1"><br />
</span></div>
<div class="p1">
<span class="s1">Other PDE5 inhibitors are already available on the market and these include Sildenafil (approved in 1998; tradename: Viagra, Revatio; ChEMBL:&nbsp;<a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL192">CHEMBL192</a>), Tadalafil (approved in 2003; tradename: Cialis; ChEMBL:&nbsp;<a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL779">CHEMBL779</a>) and Vardenafil (approved in 2003; tradename: Levitra; ChEMBL:&nbsp;<a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1520">CHEMBL1520</a>). These other PDE5 inhibitors are also approved for the treatment of pulmonary arterial hypertension (<a href="http://en.wikipedia.org/wiki/Pulmonary_arterial_hypertension">PAH</a>).</span></div>
<div class="p1">
<br /></div>
<div class="p1">
<span class="s1">PDE5 is an 875 amino acid-long enzyme (<a href="http://enzyme.expasy.org/EC/3.1.4.35">EC=3.1.4.35</a>), belonging to the cyclic nucleotide phosphodiesterase family (PFAM: <a href="http://pfam.sanger.ac.uk/family/PDEase_I">PF00233</a>).</span></div>
<div class="p1">
<span class="s1"><br />
</span></div>
<div class="p1">
<span class="s1"></span></div>
<pre style="white-space: pre-wrap; word-wrap: break-word;">&gt;PDE5A_HUMAN cGMP-specific 3',5'-cyclic phosphodiesterase
MERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKATREMVNAWFAE
RVHTIPVCKEGIRGHTESCSCPLQQSPRADNSAPGTPTRKISASEFDRPLRPIVVKDSEG
TVSFLSDSEKKEQMPLTPPRFDHDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLI
SADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEVSNNCIRLEWNKGIVGHVAALGEPL
NIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDE
KDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIIS
FMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKSSDTLTREHDANKINYMYAQYVKNTME
PLNIPDVSKDKRFPWTTENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGK
VKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETREL
QSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWIL
SVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGV
NNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAI
LATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAE
LVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCF
PLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN</pre>
<br />
<div class="p1">
<span class="s1">        </span></div>
<div class="p1">
Several crystal structures of PDE5 are now available. The catalytic domain of human PDE5 complexed with sildenafil is shown below (PDBe:<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1tbf/summary">1tbf</a>)</div>
<br />
<div class="p1">
<span class="s1"><br />
</span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-NzZ0vj2DHrs/T569G8kuWYI/AAAAAAAAAp8/DMFKP8WSZl4/s1600/PDBe_PDE5_sildenafil.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="240" src="http://4.bp.blogspot.com/-NzZ0vj2DHrs/T569G8kuWYI/AAAAAAAAAp8/DMFKP8WSZl4/s320/PDBe_PDE5_sildenafil.png" width="320" /></a></div>
<div class="p1">
<span class="s1"><br />
</span><br />
<span class="s1"></span><br />
<div class="p1">
<span class="s1"><span class="s1">Preclinical studies&nbsp;<a href="http://ac.els-cdn.com/S014929181000202X/1-s2.0-S014929181000202X-main.pdf?_tid=d78a7a81cc49dc863e3d95b4a2b516c9&amp;acdnat=1335794253_367f0e16c5e79869d62244f9bbae3afe">have shown</a>&nbsp;that Avanafil strongly inhibits PDE5 (half maximal inhibitory concentration = 5.2 nM) in a competitive manner and is 100-fold more potent for PDE5 than PDE6, which is found in the retina and is responsible for phototransduction. Also, Avanafil has shown higher selectivity (120-fold) against PDE6 than Sildenafil (16-fold) and Vardenafil (21-fold), and high selectivity (&gt;10 000-fold) against PDE1 compared with Sildenafil (380-fold) and Vardenafil (1000-fold).&nbsp;</span></span></div>
<div class="p1">
<span class="s1"><span class="s1"><br />
</span></span></div>
<div class="p1">
<span class="s1"><span class="s1">Avanafil has&nbsp;</span>also&nbsp;been reported to be a faster-acting drug than Sildenafil, with an onset of action as little as 15 minutes as opposed to 30 minutes for the other drugs.</span></div>
<div class="p1">
<span class="s1"><br />
</span></div>
</div>
<div class="p1">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-FXoPNR5dBpc/T5-0KHUPPCI/AAAAAAAAAqI/otd7Cl-U-rU/s1600/Avanafil.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="225" src="http://4.bp.blogspot.com/-FXoPNR5dBpc/T5-0KHUPPCI/AAAAAAAAAqI/otd7Cl-U-rU/s320/Avanafil.png" width="320" /></a></div>
<br />
<span class="s1">Avanafil is a synthetic small molecule, with one chiral center. Avanafil&nbsp;</span>has a molecular weight of 483.95 Da, an ALogP of 2.16, 3 hydrogen bond donors and 9 hydrogen bond acceptors and thus fully rule-of-five compliant.&nbsp;<span class="s1">(IUPAC:&nbsp;</span>4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)-pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; Canonical Smiles: COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl; InChI:&nbsp;InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-</div>
<div class="p1">
13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,</div>
<div class="p1">
16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1)</div>
<div class="p1">
<br /></div>
<div class="p1">
The recommended starting dose of Avanafil is 100 mg and should be taken orally as needed approximately 30 minutes before sexual activity. Depending on individual efficacy and tolerability, the dose can be varied to a maximum dose of 200 mg or decreased to 50 mg. The lowest dose that &nbsp;provides efficacy should be used. The maximum recommended dosing frequency is once per day.</div>
<div class="p1">
<span class="s1"><br />
</span></div>
<div class="p1">
<span class="s1">Avanafil is rapidly absorbed after oral administration, with a median T<sub>max</sub> of 30 to 45 minutes in the fasted state and 1.12 to 1.25 hours when taken with a high fat meal. Avanafil is approximately 99% bound to plasma proteins and has been found to not accumulate in plasma. It is predominantely cleared by hepatic metabolism, mainly by CYP3A4 enzyme and to a minor extent by CYP2c isoform. The plasma concentrations of the major metabolites, M4 and M16, are approximately 23% and 29% of that of the parent compound, respectively. The M4 metabolite accounts for&nbsp;</span>approximately 4% of the pharmacologic activity of Avanafil, with an <i>in vitro</i> inhibitory potency for PDE5 of 18% of that of Avanafil. The M16 metabolite has been found inactive against PDE5. After oral administration, Avanafil is excreted as metabolites mainly in the feces (approximately 62% of administrated dose) and to a lesser extent in the urine (approximately 21% of the administrated dose). Avanafil has a terminal elimination &nbsp;half-life (t<sub>1/2</sub>) of approximately 5 hours,&nbsp;which is comparable to that of Sildenafil (3-4h) and Vardenafil (4-5h), but very short relative to the very long half-life of Tadalafil (17.5h).<br />
<br />
The full prescribing information of Avanafil can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202276s000lbl.pdf">here</a>.<br />
<br />
The license holder is <a href="http://www.vivus.com/">Vivus, Inc.</a></div>
<div class="p1">
<span class="s1"><br />
</span></div>
